Pubblicazioni Scientifiche

1- Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy;

Martina Bonechi¹, Francesca Galardi¹, Chiara Biagioni², Francesca De Luca¹, Mattias Bergqvist³, Magnus Neumüller³, Cristina Guarducci¹, Giulia Boccalini¹, Stefano Gabellini¹, Ilenia Migliaccio¹, Angelo Di Leo^1,4, Marta Pestrin^1,4 and Luca Malorni^1,4

¹“Sandro Pitigliani” Translational Research Unit, Hospital of Prato, Prato, Italy ²Bioinformatics Unit, Hospital of Prato, Prato, Italy ³Biovica International, Uppsala Science Park, Uppsala, Sweden ⁴“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Prato, Italy

Oncotarget. 2018; 9:16389-16399. DOWNLOAD PDF

2- Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

L Malorni, G Curigliano, A M Minisini, S Cinieri, C A Tondini, K D’Hollander, G Arpino, A Bernardo, A Martignetti, C Criscitiello, F Puglisi, M Pestrin, G Sanna, E Moretti, E Risi, C Biagioni, A McCartney, L Boni, M Buyse, I Migliaccio, L Biganzoli, A Di Leo;

Annals of Oncology, , mdy214, https://doi.org/10.1093/annonc/mdy214
 

3- Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial

Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo and Luca Malorni

American Association for Cancer Research, https://clincancerres.aacrjournals.org/content/early/2020/01/14/1078-0432.CCR-19-3271